MicroRNA-21与骨质疏松症相关性的研究进展

骨质疏松症(osteoporosis,OP)是一种以易骨折为特点的全身代谢性骨骼疾病。在老龄化程度不断加剧的当今社会,其发病率逐年呈现显著上升趋势,尤其是骨质疏松性骨折导致的后遗症、副损伤给社会及患者带来极大的经济和生活负担。近年来诸多研究发现microRNA具有明确的抗骨质疏松作用,随着基因疗法应用的推广,microRNA在临床治疗骨质疏松起到了很好的靶向作用,同时相关文献阐释,尤其是其家族成员microRNA-21可通过调控成骨细胞和破骨细胞的分化与功能,在OP等骨疾病的发生发展过程中起着重要作用。本文将通过对microRNA-21在骨质疏松中的相关作用机制进行综述,旨在为OP靶向治疗及相关分子机制研究提供理论依据和新的思路。

Research progress of the correlation between microRNA-21 and osteoporosis

Osteoporosis (OP) is a common systemic metabolic bone disease characterized by bone loss, bone tissue microstructural damage, increased bone fragility, and easy fracture. With the increasing aging, its incidence has shown a significant upward trend year by year. Sequelae and Deputy injury caused by osteoporotic fractures have brought great economic and living burden to society and patients. In recent years, many studies have found that microRNAs have a clear anti-osteoporosis effect. With the promotion of gene therapy, microRNA plays a key role in the clinical treatment of osteoporosis, and related literature illustrates the family member microRNA-21 can play an important role in the development and progression of bone diseases, such as OP by regulating the differentiation and function of osteoblasts and osteoclasts. This article will review the related mechanisms of microRNA-21 in osteoporosis, aiming to provide theoretical basis and new research ideas for OP targeted therapy and related molecular mechanisms.